Bausch Health completes DURECT acquisition for $63 million Sep 11, 2025 08:35AM
Bausch Health Completes Acquisition of DURECT Corporation, Expanding Late-stage Liver Disease Portfolio Sep 11, 2025 08:35AM
Bausch Health Announces Extension of DURECT Corporation Tender Offer to September 10, 2025 Aug 26, 2025 08:00AM
DURECT Corporation Reports Second Quarter 2025 Financial Results and Provides Update on Proposed Acquisition by Bausch Health Aug 12, 2025 04:30PM
Bausch Health to acquire DURECT for $63 million upfront Jul 29, 2025 07:01AM
View Older Stories

Jul 29, 2025 07:00AM Bausch Health to acquire DURECT for $63 million upfront
Jul 29, 2025 07:00AM Bausch Health to Acquire DURECT Corporation, Strengthening Commitment to Developing Innovative Solutions for Patients with Liver Disease
Jul 29, 2025 07:00AM Bausch Health to Acquire DURECT Corporation, Strengthening Commitment to Developing Innovative Solutions for Patients with Liver Disease
May 13, 2025 04:05PM DURECT Corporation Reports First Quarter 2025 Financial Results and Provides Business Update
Mar 26, 2025 04:05PM DURECT Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Mar 19, 2025 04:30PM DURECT Corporation to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide a Business Update
Feb 4, 2025 07:30AM DURECT Corporation to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
Jan 28, 2025 10:10AM DURECT Corp (DRRX) Announces Publication of Larsucosterol Phase 2b Results in NEJM Evidence
Jan 28, 2025 10:09AM DURECT Corporation Announces Publication of Larsucosterol Phase 2b Results in NEJM Evidence
Nov 25, 2024 06:32AM DURECT Corp (DRRX) Sells ALZET Product Line to Lafayette Instrument Co. for $17.5M
Nov 25, 2024 06:00AM DURECT Corporation Announces Sale of ALZET® Product Line to Lafayette Instrument Co. for $17.5 Million
Nov 13, 2024 04:01PM DURECT Corporation Reports Third Quarter 2024 Financial Results and Provides Business Update
Nov 6, 2024 04:45PM DURECT Corporation to Announce Third Quarter 2024 Financial Results and Provide a Business Update
Oct 17, 2024 08:30AM DURECT Corporation to Present Data on Larsucosterol at The Liver Meeting 2024
Sep 25, 2024 08:00AM DURECT Corporation Announces Phase 3 Registrational Trial Design for Larsucosterol in Alcohol-associated Hepatitis
Sep 4, 2024 04:30PM DURECT Corporation to Present at the H.C. Wainwright Global Investment Conference
Aug 13, 2024 04:01PM DURECT Corporation Reports Second Quarter 2024 Financial Results and Business Update
Aug 7, 2024 04:30PM DURECT Corporation to Announce Second Quarter 2024 Financial Results and Provide a Business Update
May 21, 2024 08:02AM DURECT Corp (DRRX) Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis
May 21, 2024 08:00AM DURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis
May 13, 2024 04:05PM DURECT Corporation Reports First Quarter 2024 Financial Results and Business Update
May 7, 2024 04:30PM DURECT Corporation to Announce First Quarter 2024 Financial Results and Provide a Business Update
Apr 30, 2024 07:00AM DURECT Corporation Announces Late-Breaking Oral Presentation at the EASL Congress 2024 to Discuss AHFIRM Phase 2b Data in Alcohol-Associated Hepatitis
Mar 27, 2024 04:01PM DURECT Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Mar 20, 2024 04:30PM DURECT Corporation to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update
Mar 4, 2024 07:00AM DURECT and Charles River Laboratories Enter into Co-Marketing and Collaboration Agreement for ALZET® Product Line in U.S. and Canada
Feb 7, 2024 06:48PM DURECT Corporation to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Nov 13, 2023 04:05PM DURECT Corporation Reports Third Quarter 2023 Financial Results and Business Update
Nov 9, 2023 04:30PM DURECT Corporation to Announce Third Quarter 2023 Financial Results and Provide a Business Update
Nov 7, 2023 04:02PM DURECT Corp (DRRX) Reports Topline Results from Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis with Promising Effect on Mortality
Nov 7, 2023 04:01PM DURECT Corporation Announces Topline Results from Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis with Promising Effect on Mortality
Sep 7, 2023 07:00AM DURECT Corporation Announces Last Patient Last Visit in Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis
Aug 31, 2023 04:30PM DURECT Corporation Announces Presentations in Upcoming Investor Conferences
Aug 9, 2023 04:05PM DURECT Corporation Reports Second Quarter 2023 Financial Results and Business Update
Aug 3, 2023 04:30PM DURECT Corporation to Announce Second Quarter 2023 Financial Results and Provide a Business Update
May 8, 2023 04:05PM DURECT Corporation Reports First Quarter 2023 Financial Results and Business Update
May 1, 2023 07:03PM DURECT Corporation to Announce First Quarter 2023 Financial Results and Provide Business Update on May 8
Apr 27, 2023 05:11PM DURECT Corporation to Host KOL Event on Alcohol-Associated Hepatitis
Apr 25, 2023 06:45PM DURECT Corporation to Participate in Fireside Chat at the H.C. Wainwright BioConnect Investor Conference
Apr 10, 2023 06:00AM DURECT Corp (DRRX) Announces Peer-Reviewed Publication of Additional Data from Previously Completed Phase 2a Study of Larsucosterol
Apr 10, 2023 06:00AM DURECT Announces Peer-Reviewed Article Accepted for Publication with Additional Data from Previously Completed Phase 2a Study of Larsucosterol in Alcohol-Associated Hepatitis
Mar 21, 2023 04:30PM DURECT Corp (DRRX) Appoints Gail Maderis as Board Chair
Mar 21, 2023 04:30PM DURECT Corporation Announces Appointment of Gail Maderis as Chair of the Board
Mar 9, 2023 08:30AM DURECT Corporation Fireside Chat at the Oppenheimer 33rd Annual Healthcare Conference
Mar 7, 2023 04:05PM DURECT Corporation Reports Fourth Quarter and Full Year 2022 Financial Results and AHFIRM Trial Update
Feb 28, 2023 06:07PM DURECT Corporation to Announce Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 7
Nov 29, 2022 06:21AM DURECT Corp (DRRX) Announces 1-for-10 Reverse Stock Split
Nov 28, 2022 06:46PM DURECT Announces 1-for-10 Reverse Stock Split
Nov 2, 2022 04:05PM DURECT Corporation Reports Third Quarter 2022 Financial Results and Update of Programs
Oct 26, 2022 08:30AM DURECT Corporation to Announce Third Quarter 2022 Financial Results and Provide Business Update on November 2
View Older Stories